Inozyme Pharma Posts Encouraging Data From Rare Calcification Disorders
Portfolio Pulse from Vandana Singh
Inozyme Pharma Inc (NASDAQ: INZY) has announced positive interim data from its ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency. The data shows a meaningful reduction of fibroblast growth factor-23 (FGF-23) and an increase in serum phosphate levels. The company also reported upward trends in bone-specific alkaline phosphatase levels and improvements in GIC scores. The data suggests clinical benefits for ENPP1 Deficiency, including improvement in key biomarkers, patient-reported outcomes, and functional outcomes. Following the news, INZY shares are up 10.60% at $4.77.
September 26, 2023 | 6:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inozyme Pharma's positive interim data from its ongoing Phase 1/2 trials of INZ-701 has led to a 10.60% increase in its share price.
The positive interim data from Inozyme Pharma's ongoing Phase 1/2 trials of INZ-701 for ENPP1 and ABCC6 Deficiencies has shown promising results, which has likely led to increased investor confidence and a subsequent rise in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100